3[1]Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy of local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol, 1997, 15: 2483.
4[2]Hortobagyi GN. Drug therapy: treatment of breast can cer. N Engl J Med, 1998, 339: 974.
5[3]Fisher B. The evolution of paradigms for the management of breast cancer: A personal perspective. Cancer Res, 1992, 52: 2371.
6[4]Bonadonna G. Evolving concepts in systemic adjuvant treatment of breast cancer. Cancer Res, 1992, 52: 2127.
7[5]Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusionalchemotherapy for large early breast cancer. J Clin Oncol, 1995, 13: 424.
8[6]Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: Preliminary results of a randomized trials: S6. Eur J Cancer, 1994, 30A: 645.
9[7]Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl CancerInst, 1990, 82: 1539.
10[8]Shao ZM, Li J, Wu J, et al. Primary chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat, 1999, 1288: 1.
1[5]Joish VN,Oderda GM.Cost-utility analysis and quality adjusted life years[J].J Pain Palliat Care Pharmacother,2005,19(1):57-61.
2[6]Nagar S,Blanchard RL.Pharmacogenetics of Uridine Diphosphoglucuronosyltransferase (UGT) 1A Family Members and its Role in Patient Response to Irinotecan[J].Drug Metab Rev,2006,38:393-409.
3[7]Boughey JC,Peintinger F,Meric-Bernstam F,Perry AC,Hunt KK,Babiera GV,Singletary SE,Bedrosian I,Lucci A,Buzdar AU,Pusztai L,et al.Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer[J].Ann Surg,2006,244:464-470.
